Novel Hormonal Therapies for nmCRPC Underused, Data Show
Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.
Androgen-deprivation Therapy
Survival Improving in Metastatic Castration-Sensitive Prostate Cancer Population
Increase in survival of men with mCSPC during 2015-2019 coincides with the use of docetaxel and novel hormonal therapies for this disease state.
Longer Course of ADT With Postop Radiotherapy Improves Metastasis-Free Survival in Prostate Cancer
Adding a longer course of androgen deprivation therapy to postoperative radiotherapy may prolong metastasis-free survival in patients with prostate cancer.
ADT Use for Prostate Cancer Linked to Increased Risk for CVD Death
Risk increased for CVD death and for death from ischemic heart disease and stroke, especially among those aged 70 to 79 years
Abiraterone and Enzalutamide Raise Metabolic, Cardiovascular Adverse Event Risks
A report in the Journal of the National Cancer Institute presents findings from the first assessment of the real-world safety of abiraterone and enzalutamide in a national sample of Medicare beneficiaries with advanced prostate cancer.
Depression, Anxiety Rates High With Androgen Deprivation Therapy for Prostate Cancer
An analysis of data discovered a link between treatment with androgen deprivation therapy and new diagnoses of incident depression and anxiety in men with prostate cancer.
Benefit of Long-Term ADT Varies by Risk Group in Localized Prostate Cancer
There was no significant benefit with long-term ADT, but researchers said there was a “clinically relevant” benefit in patients with high-risk disease.
DXA Screening Rate Low Among Older Men Initiating Prostate Cancer ADT
Study confirms the care gap in bone health management and fracture prevention among older men with prostate cancer receiving androgen deprivation therapy.
Neoadjuvant Abiraterone Prior to Surgery Beneficial in High-Risk Prostate Cancer
In a phase 2 trial, 44% of men who received abiraterone with or without cabazitaxel prior to radical prostatectomy for high-risk prostate cancer achieved a pathologic complete response or minimal residual disease.
Prostate Cancer ADT Plus Radiation Improves Metastasis-Free Survival
The meta-analysis, however, showed no clear oncologic benefit to prolonging neoadjuvant ADT before definitive radiation therapy for prostate cancer.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...